Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 10/20 | 0.53 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30583912 | 0.88 | DPP4 (0.45) | GLP1RTRPV3MAPTCNR1NPSR1 | |
| SCHEMBL24455270 | 0.88 | GPR119 (0.57) | GLP1RTRPV3GPR119 | |
| SCHEMBL22391791 | 0.88 | TRPV3 (0.47) | GLP1RTRPV3MAPTCNR1NPSR1 | |
| SCHEMBL20266522 | 0.88 | GLP1R (0.58) | GLP1R | |
| SCHEMBL24321002 | 0.88 | GPR119 (0.46) | GLP1RTRPV3MAPTCNR1NPSR1 | |
| SCHEMBL30209321 | 0.88 | TRPV3 (0.47) | GLP1RTRPV3MAPTCNR1NPSR1 | |
| SCHEMBL29668681 | 0.88 | GLP1R (0.58) | GLP1R | |
| SCHEMBL27111260 | 0.86 | CACNB4 (0.49) | DPP4GPR119CYP3A4CYP3A5 | |
| SCHEMBL23928974 | 0.85 | FNTA (0.46) | MAPTCNR1NPSR1USP30DPP4 | |
| SCHEMBL31670786 | 0.84 | GLP1R (0.46) | GLP1RTRPV3MAPTCNR1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-12-07 | — | — | US | disclosed |
| WO-2022078407-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | GLP1R 1/4885TRPV3 410/4885MAPT 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.